Accretion PharmaceuticalsNSE:ACCPL -1.81%18 ROA % is 14.49% as of Mar. 2026, which is 15% above its 10-year median of 12.61. GuruFocus rates NSE:ACCPL with a GF Score™ of 18/100. The stock has 6 warning signs investors should review. Among 1,006 Drug Manufacturers companies, Accretion Pharmaceuticals ranks better than 91.15% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Accretion Pharmaceuticals's annualizedNet Income for the quarter that ended in Mar. 2026 was ₹98.3 Mil.
Accretion Pharmaceuticals's average Total Assets over the quarter that ended in Mar. 2026 was ₹678.7 Mil. Therefore, Accretion Pharmaceuticals's annualized ROA % for the quarter that ended in Mar. 2026 was 14.49%.
The historical rank and industry rank for Accretion Pharmaceuticals's ROA % or its related term are showing as below:
NSE:ACCPL'
s ROA % Range Over the Past 10 Years
Min: 0.45 Med: 12.61 Max: 25.12
Current: 14.25
During the past 5 years, Accretion Pharmaceuticals's highest ROA % was 25.12%. The lowest was 0.45%. And the median was 12.61%.
NSE:ACCPL's ROA % is ranked better than 91.15% of 1006
companies
in the Drug Manufacturers industry
Industry Median: 2.685
vs NSE:ACCPL: 14.25
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is two times the semi-annual (Mar. 2026) net income data. The Revenue data used here is two times the semi-annual (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Accretion Pharmaceuticals's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Accretion Pharmaceuticals ROA % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Accretion Pharmaceuticals's ROA % distribution charts can be found below:
* The bar in red indicates where Accretion Pharmaceuticals's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
Accretion Pharmaceuticals (NSE:ACCPL) has a ROA % of 14.49% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Accretion Pharmaceuticals and its competitors. This is 15% above median its historical median of 12.61. Over the past decade, Accretion Pharmaceuticals' ROA % has ranged from 0.45 to 25.12. According to the industry distribution chart, Accretion Pharmaceuticals ranks #89 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 8.8%.
Is Accretion Pharmaceuticals' ROA % too high?
Accretion Pharmaceuticals' current ROA % of 14.49% is 15% above median its 10-year median of 12.61. Over the past 10 years, this metric has ranged from a low of 0.45 to a high of 25.12. The Drug Manufacturers industry median ROA % is 2.69. Accretion Pharmaceuticals' value of 14.49% is 439.7% above this industry median. Based on the distribution chart, Accretion Pharmaceuticals ranks #89 out of 1006 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Accretion Pharmaceuticals has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Accretion Pharmaceuticals' ROA % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Accretion Pharmaceuticals ranks #89 out of 1006 companies for ROA %. This places Accretion Pharmaceuticals in the top 9% of its industry — outperforming the majority of peers. The industry median ROA % is 2.69. Accretion Pharmaceuticals' value of 14.49% is 439.7% above this benchmark. Historically, Accretion Pharmaceuticals' own ROA % has ranged from 0.45 to 25.12 over the past decade. While the company's 10-year median is 12.61 vs. the industry median of 2.69, Accretion Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Drug Manufacturers company?
The median ROA % among Drug Manufacturers companies is 2.69, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Accretion Pharmaceuticals's current ROA % of 14.49% is 439.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Accretion Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median ROA % is 2.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Accretion Pharmaceuticals's current ROA % is 14.49%, which is 15% above median its own 10-year median of 12.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Accretion Pharmaceuticals stock overvalued right now?
Accretion Pharmaceuticals (NSE:ACCPL) has a current ROA % of 14.49%. The current ROA % is 14.49%, which is 15% above median its 10-year median of 12.61 and 439.7% above the Drug Manufacturers industry median of 2.69. Accretion Pharmaceuticals' overall GF Score™ is 18/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Accretion Pharmaceuticals (NSE:ACCPL), the current ROA % is 14.49% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Accretion Pharmaceuticals Ltd is engaged in the manufacturing of Medicinal & Pharmaceutical Products. The company manufactures tablets, oral liquid, capsule, cream, ointment, mouthwash, dusting powder, gel, ear drops, lotion, shampoo, powder, syrup, among others.
18GF Score
Get the complete analysis for NSE:ACCPL
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ACCPL has been successfully added to your 